Advertisement
ImmunityBio, Inc.

ImmunityBio, Inc. (IBRX) Stock Overview

Explore ImmunityBio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

IBRXNASDAQ
HealthcareBiotechnology
$7.80
$0.48(6.56%)
U.S. Market opens in 7h 43m
Advertisement

ImmunityBio, Inc. (IBRX)

Meyka AI Score

Z

Key Financials

Market Cap8.2B
P/E Ratio-9.23
EPS (TTM)$-0.32
ROE1.39%
Fundamental Analysis

AI Price Forecasts

1 Month$7.30
3 Months$9.41
1 Year Target$5.20

IBRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of ImmunityBio, Inc. (IBRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 57.10, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $5.20.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -9.23 and a market capitalization of 8.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
6.56%
5-Day Change
4.14%
1-Month Change
8.03%
3-Month Change
5.12%
6-Month Change
264.49%
Year-to-Date (YTD) Change
293.94%
1-Year Change
179.57%
3-Year Change
201.16%
5-Year Change
-46.28%
All-Time (Max) Change
-77.48%

Contact Information

858 633 0300
3530 John Hopkins Court, San Diego, CA, 92121

Company Facts

6,710 Employees
IPO DateJul 28, 2015
CountryUS
Actively Trading

Frequently Asked Questions